Q2 FY2026 EarningsQ2 FY2026 outperformed consensus on the top-line with total revenue of $92.1M vs. $90.1M expected, driven by Recorlev's 81% YoY growth. Gross margin of 86% was slightly below the 87.04% mean estimate but represented a significant expansion from 82% YoY. GAAP EPS was a miss at -$0.18 vs. $0.003 expected due to a $31M one-time debt-related charge. Full-year revenue guidance was tightened to $385M–$390M, signaling confidence in sustained commercial momentum.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Xeris Biopharma(XERS) the Revenue is 92.1 M (+28.74%), Beat estimate;the EBIT is 5.173 M (+15.42%), Miss estimate;the EPS is -0.18 (-1700%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.09B28.74%
0.09B25.98%
+0.00B2.76%
EBITMiss expectations
0.01B15.42%
0.01B45.23%
-0.00B29.81%
EPSMiss expectations
-0.181700.00%
0.0033133.30%
-0.18331,833.30%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf